Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TALENT: transbronchial needle injection of tremelimumab in early-stage NSCLC
NL-OMON60178Phase 2Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of tremelimumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Safety and Feasibility. Started Nov 2025; status: recruiting.
02
Drugs
tremelimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON60178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60178.